How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,182 results for

Topical NSAID

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Is there any role for topical non-steroidal anti-inflammatory drugs in the treatment of mild to moderate musculoskeletal pain in a Lebanese community pharmacy? Full Text available with Trip Pro

Is there any role for topical non-steroidal anti-inflammatory drugs in the treatment of mild to moderate musculoskeletal pain in a Lebanese community pharmacy? Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed in the community pharmacy. Their systemic administration has been related to significant adverse effects. The aim of this study was to evaluate the efficacy of topical NSAIDs in managing mild to moderate musculoskeletal pain versus systemic administration or combination (...) of both routes.This was a prospective observational study conducted in a large Lebanese community pharmacy over a period of 5 months in 302 patients. Participants were divided into three groups according to their route of administration of NSAIDs either topically, systemically or combination of both. During follow up period, degree of pain, efficacy of NSAID therapy, side effects, onset time and duration of pain relief reported by each patient were collected by the study investigators using specific

2016 SpringerPlus

182. Pain Perception in Phacoemulsification with Topical Anesthesia and Evaluation of Factors Related with Pain Full Text available with Trip Pro

, moderate and intense pain was 35.9%, 25.0% and 17.4%, respectively. The average verbal pain score during the surgery was 1.4±1.0 (0-3). Reported pain level was not associated with age or gender (p>0.05). Diabetic patients and patients who consumed nonsteroidal anti-inflammatory drugs in the morning before operation reported less pain during and after the surgery (p<0.05). There were no complications except posterior capsule rupture in one patient. Duration of surgery was longer in patients who reported (...) Pain Perception in Phacoemulsification with Topical Anesthesia and Evaluation of Factors Related with Pain Evaluation of pain during and after phacoemulsification with topical anesthesia in patients with senile cataract and investigation of factors related with pain.Ninety-two adult patients scheduled for routine clear corneal phacoemulsification with topical anesthesia who had no previous cataract surgery in their fellow eyes were included in the study. Verbal pain scale and visual analog

2016 Turkish Journal of Ophthalmology

183. Study of a New Medical Device in Gel Formulation Versus Calgel® for the Topical Treatment of Teething in Infants

and/or immobilization and/or confinement to bed. Infants with known history of severe renal insufficiency and/or known history of severe cardiac dysfunction and/or liver problems Use of topical Lidocaine and/or topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) within one day before inclusion. Use of systemic NSAIDs within 3 days before inclusion and/or use of systemic anesthetics within 10 days before. Concomitant use during the period of study of NSAIDs and/or any anesthetics (obviously Calgel® is allowed (...) Phase Pain Teeth Device: Hyaluronic Acid 0.54% Drug: Calgel® Phase 3 Detailed Description: Due to the potentially serious toxicity that can result from the use of topical anesthetics to relieving the symptoms associated with gingival inflammatory conditions or gums trauma in infant, recently, products containing Hyaluronic Acid have been marketed in Europe. In particular, Ricerfarma is developing several high molecular weight Hyaluronic Acid medical devices characterized by the absence

2016 Clinical Trials

184. A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel

of acne vulgaris on the face within 14 days of baseline Use of systemic corticosteroids, antibiotics, anti-acne drugs, anti-inflammatory drugs (NSAIDs are permitted) or prescription topical retinoid use on the face within 28 days prior the baseline Initiation of hormonal therapy or dose change to hormonal therapy within 12 weeks prior to baseline. Use of androgen receptor blockers (eg, spironolactone, flutamide) within 12 weeks prior to baseline Use of oral retinoid (eg, isotretinoin, alitretinoin (...) between 18 and 50, inclusive Male or female, agree to comply with contraceptive requirements Signed Informed Consent Form Clinical diagnosis of facial acne vulgaris defined as: 25 to 75 inflammatory lesions, 20 to 120 non-inflammatory lesions, and an IGA score of ≥3 Agree to refrain from using any topical acne treatments on the face or any oral acne treatments. Topical acne treatment that do not have significant or measurable systemic absorption are permitted for treatment of the back, shoulders

2016 Clinical Trials

185. Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1%

Diseases Diclofenac Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action (...) by (Responsible Party): Akorn, Inc. Study Details Study Description Go to Brief Summary: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Three-Arm, Multi-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Topical Gel 1% (Hi-Tech Pharmacal Co., Inc.) With Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in Patients With Osteoarthritis of the Knee Condition or disease Intervention/treatment Phase Osteoarthritis, Knee Drug: Diclofenac Sodium Gel 1% Drug: Voltaren

2016 Clinical Trials

186. A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

supplements, systemic use of steroids, chronic use of NSAIDS, any antihypertensive agents, such as beta-blockers, diuretics, ACE inhibitors, CA channel blockers, Alpha blockers, Central Acting agents and vasodilators. Ability to comprehend and comply with procedures Agree to commit to participate in the current protocol Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects (...) A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2016 Clinical Trials

187. Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery

, Childhood Cataract Program of the Chinese Ministry of Health(CCPMOH), Zhongshan Ophthalmic Center, Sun Yat-sen University ClinicalTrials.gov Identifier: Other Study ID Numbers: CCPMOH2016-China-1 First Posted: February 12, 2016 Last Update Posted: February 12, 2016 Last Verified: February 2016 Additional relevant MeSH terms: Layout table for MeSH terms Cataract Lens Diseases Eye Diseases Pharmaceutical Solutions Ophthalmic Solutions Bromfenac Dinoprostone Anti-Inflammatory Agents, Non-Steroidal (...) Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Oxytocics Reproductive Control Agents

2016 Clinical Trials

188. The Effect of Topical Doxycycline Gel on HbA1c in Patients With Type 2 Diabetes Mellitus(DM) ®

. Exclusion Criteria: Pregnancy or lactation History of allergy to drugs used in the study Smoking Diabetes-related emergency within 30 days ago Use of nonsteroidal anti-inflammatory drugs Or taking low dose daily aspirin (75-325 mg)\ Use of immunosuppressive medications; antibiotic use Dialysis Risk of bleeding complications The type of disease periodontal (Aggressive) A history of periodontal treatment in the previous 6 months Orthodontic treatment Using the removal prostheses Extensive dental caries (...) gel, After 12 weeks their periodontal condition and Fasting blood sugar (FBS), glycated hemoglobin (HbA1c) level, will be reevaluated. Condition or disease Intervention/treatment Phase Diabetes Mellitus With Periodontal Disease Drug: Doxycycline Group Drug: placebo topical gel Phase 2 Phase 3 Detailed Description: Doxycycline downregulates the activity of matrix metalloproteinases (MMPs), key destructive enzymes in periodontal disease Study Design Go to Layout table for study information Study

2016 Clinical Trials

189. Topical Menthol +/- Mannitol for Painful Diabetic Peripheral Neuropathy

Topical Menthol +/- Mannitol for Painful Diabetic Peripheral Neuropathy Topical Menthol +/- Mannitol for Painful Diabetic Peripheral Neuropathy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical (...) cream with mannitol added for 3 months with a crossover for 3 additional months. At time 0, 1,4 and 7 months their BPI pain severity and interference scores, DN4 scores, cream % effectiveness and side effects will be compared. Condition or disease Intervention/treatment Phase Diabetic Peripheral Neuropathy Drug: Mannitol Drug: Menthol Phase 1 Phase 2 Detailed Description: Purpose: to find out if a menthol cream containing mannitol is more effective than the same cream without mannitol in relieving

2016 Clinical Trials

190. Effect of Topical and Oral Diclofenac on Pain Related to Intravitreal Injections

. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the activity of cyclooxygenase-1 and cyclooxygenase-2, and thereby, the synthesis of prostaglandins and thromboxanes. Cyclooxygenase-2 inhibition leads to the anti-inflammatory, analgesic and antipyretic effects of NSAIDs. Ophthalmic NSAIDs constitute an established and effective treatment option for the management of inflammation and pain associated with cataract surgery and of pain associated with corneal refractive surgery, for inhibition (...) . Georgakopoulos, MD, PhD, University Hospital of Patras: pain intravitreal injection anti-VEGF diclofenac eye drops oral diclofenac Short Form of McGill Pain Questionnaire Additional relevant MeSH terms: Layout table for MeSH terms Ophthalmic Solutions Diclofenac Lubricant Eye Drops Pharmaceutical Solutions Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic

2016 Clinical Trials

191. Topical "Non-Aromatic Very Rich in Steranes" (NAVS) Naphthalan for the Treatment of Oral Mucosal Diseases

, hepatobiliary system diseases, lichenoid reaction (amalgam, drugs) or lichen planus with lesions in contact to restorative materials (Zakrzewska et al, 2005), the current comparative systemic or local anti-inflammatory treatment (antibiotics, corticosteroids, non-steroidal antirheumatic drugs, chemotherapeutics) (Lo Muzio et al, 2001; Nolan et al, 2006; Rodriguez et al, 2007) and pregnancy. for RAS patients: patients younger than 18 years, haematological deficits (assessed by complete blood count (CBC (...) the other half will receive 0.05%-betamethasone dipropionate in adhesive paste. Our hypothesis is that NAVS could be efficient in the treatment of OLP and RAS, with effects comparable to that of topical steroids. Condition or disease Intervention/treatment Phase Oral Lichen Planus Recurrent Aphthous Stomatitis Drug: NAVS Naphthalan Drug: 0.05% Betamethasone dipropionate Phase 2 Detailed Description: Non-Aromatic-Very rich in Steranes (NAVS) naphthalan is a transparent, earth mineral oil prepared

2016 Clinical Trials

192. Study of X0002 Following Escalating Single and Multiple Doses Administered as Topical Application in Healthy Volunteers

metabolizing enzymes, such as grapefruit or grapefruit drink. Can the use of acetaminophen, but must record report in case report form (CRF); A history of gastrointestinal bleeding or peptic ulcers, drugs allergy for aspirin or hypersensitivity to aspirin or other NSAIDs (Non-Steroidal Antiinflammatory Drugs), or a history of asthma or other allergic-type reactions after taking aspirin or other NSAIDs(Non-Steroidal Antiinflammatory Drugs); A history of intolerance or hypersensitivity to ibuprofenamine (...) Completion Date : March 2017 Actual Study Completion Date : March 29, 2017 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: X0002 First Dose Preliminary Experiment,4 Subjects,Single-Dose,Once,Non-Blind. Drug: X0002 External Spray Experimental: X0002 Second Dose 8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind. Drug: X0002 External Spray Placebo Comparator

2016 Clinical Trials

193. Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections

(IVI) is a preferred route of administration of drugs in the posterior segment of the eye. Intravitreal injection of anti-VEGFs constitutes the mainstay for the treatment of various retinal diseases such as AMD, RVO, DME etc. The procedure of the IVI is, however, associated with a level of discomfort for the patient. Ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) constitute an established and effective treatment option for the management of inflammation and pain associated with cataract (...) of Patras: intravitreal injection pain non-steroidal anti-inflammatory drugs anti-VEGF nepafenac Additional relevant MeSH terms: Layout table for MeSH terms Ophthalmic Solutions Lubricant Eye Drops Nepafenac Pharmaceutical Solutions Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents

2016 Clinical Trials

194. Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid Arthritis

non-steroidal anti-inflammatory drugs (NSAIDs) or orally Chinese herbal medicine, then the doses should have been kept stable for at least 4 weeks. Exclusion Criteria: Skin allergies or broken skin; Taking TwHF agents, glucocorticoids and biological agents; Female patients who are pregnant, breast-feeding or planed to be pregnant; Subjects suffering serious hyperlipidemia, hyperglycemia, diabetes mellitus, cardiovascular diseases, gastrointestinal problems or liver and renal failure. Contacts (...) , and take its advantage to make TwHF topically in order to get an effective and safe treatment for active RA patients. Condition or disease Intervention/treatment Phase Arthritis, Rheumatoid Drug: Topical tripterygium gel Drug: Placebo gel Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 70 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary

2016 Clinical Trials

195. Hot Topics in Primary Care: Update on the Recognition and Management of Gout: More Than the Great Toe. (Abstract)

Hot Topics in Primary Care: Update on the Recognition and Management of Gout: More Than the Great Toe. Gout is a chronic inflammatory condition that is increasing in prevalence and commonly associated with other chronic diseases such as obesity, diabetes mellitus, hypertension, hypercholesterolemia, chronic kidney disease, cardiovascular disease, and thromboembolic disorders. These associations make the management of patients with gout more complex. Although identification of MSU crystals (...) in synovial fluid is diagnostic, a presumptive diagnosis of gout can be made clinically based on the presence of hyperuricemia, rapid development of pain, tenderness, and swelling in a single toe (male) or elbow or finger joint (female), and family history. Gout is increasingly recognized as a heterogeneous disease requiring individualized treatment. A healthy lifestyle is always recommended and patient education is critical to support self-management and long-term adherence. Antiinflammatory therapy

2015 Journal of Family Practice

196. REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1. Full Text available with Trip Pro

REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1. To assess vitreous concentrations of nonsteroidal anti-inflammatory drugs (NSAIDs) and prostaglandin E2 (PGE2) in patients treated with NSAIDs before vitrectomy for macular pucker.A prospective, investigator-masked, randomized study was performed in 64 patients scheduled to undergo vitrectomy. The patients were randomized 1:1:1:1 to receive indomethacin 0.5 (...) %, bromfenac 0.09%, nepafenac 0.1%, or placebo three times a day. NSAIDs and PGE2 levels were evaluated in vitreous samples collected at the beginning of surgery.Mean (SD) vitreous concentrations of the study drugs were 503.13 (241.1) pg/mL for indomethacin, 302.5 (91.03) pg/mL for bromfenac, and 284.38 (128.2) pg/mL for nepafenac. Mean (SD) vitreous PGE2 levels were 247.9 (140.9) pg/mL for indomethacin, 322.12 (228.1) pg/mL for bromfenac, 448.8 (261.1) pg/mL for nepafenac, and 1,133 (323.9) pg/mL

2015 Retina Controlled trial quality: uncertain

197. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification. (Abstract)

randomized case series.Patients with age-related cataract having phacoemulsification with PC IOL implantation were randomized into 4 groups receiving topical ketorolac 0.4% (Group A), bromfenac 0.09% (Group B), nepafenac 0.1% (Group C), or no nonsteroidal antiinflammatory drugs (NSAIDs) (Group D, control). The topical NSAIDs were started 1 day prior to the surgery and continued for 6 weeks postoperatively. All patients received a standard regimen of moxifloxacin 0.5% (Vigamox) and prednisolone acetate (...) NSAID groups and the no-NSAID group (P = .032 at 4 weeks and P = .252 at 8 weeks).The topical NSAIDs ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1% were effective for the reduction of postoperative inflammation following phacoemulsification. Compared with ketorolac tromethamine, bromfenac, and the control, nepafenac was significantly effective 1 month postoperatively in reducing anterior chamber flare, as evidenced by decreased laser flare photometry.No author has a financial or proprietary

2015 Journal of cataract and refractive surgery Controlled trial quality: uncertain

198. Efficacy and safety of diclofenac sodium 2% topical solution for osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled, 4 week study. (Abstract)

Efficacy and safety of diclofenac sodium 2% topical solution for osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled, 4 week study. Nonsteroidal anti-inflammatory drugs (NSAIDs) are standard therapy for osteoarthritis (OA). Topically applied NSAIDs reduce systemic exposure compared with oral NSAIDS, and European guidelines recommend their use. The NSAID diclofenac is available in a range of topical formulations. Diclofenac 1% gel and 1.5% four times daily and 2% twice (...) daily (BID) solutions are approved to reduce pain from OA of the knee(s). The objective of this study was to investigate the efficacy and safety of diclofenac sodium 2% topical solution BID versus vehicle control solution for treating pain associated with OA of the knee.A phase II, 4 week, randomized, double-blind, parallel-group, two-arm, vehicle-controlled study compared pain relief with diclofenac sodium 2% topical solution versus control (vehicle only) in patients aged 40 to 85 years

2015 Current medical research and opinion Controlled trial quality: predicted high

199. Topical diclofenac does not affect the antiplatelet properties of aspirin as compared to the intermediate effects of oral diclofenac: A prospective, randomized, complete crossover study. (Abstract)

Topical diclofenac does not affect the antiplatelet properties of aspirin as compared to the intermediate effects of oral diclofenac: A prospective, randomized, complete crossover study. Nonsteroidal anti-inflammatory drugs (NSAIDs) adversely interact with aspirin, diminishing its antiplatelet effect and potentially placing patients at an increased risk for recurrent thrombotic events. This crossover study aimed to determine whether the topical NSAID diclofenac epolamine 1.3% patch or oral (...) in platelet function was observed following the diclofenac patch and aspirin vs aspirin alone. Oral diclofenac produced a mixed effect with significant reduction in platelet inhibition at hour 2 and hour 8 following aspirin administration. Topical diclofenac does not significantly interfere with the antiplatelet effects of aspirin and may be a safer alternative to the oral formulation.© 2015, The American College of Clinical Pharmacology.

2015 Journal of clinical pharmacology Controlled trial quality: uncertain

200. A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

clinical depression within 2 years or are currently undergoing treatment for depression; Have a hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs, including aspirin) or hypersensitivity to acetaminophen. Have used opioids within 72 hours prior to the Baseline / Day 1 visit or during the course of the study. Have used oral or injected corticosteroids chronically or intermittently within the past 60 days (oral), or 90 days (injected). Are a current drug or alcohol abuser. Are pregnant (...) ): Frontier Biotechnologies Inc. Study Details Study Description Go to Brief Summary: The objectives of this study are to examine the safety, tolerability, and efficacy of repeated topical administration of AB001 topical patches for the treatment of chronic low back pain. Condition or disease Intervention/treatment Phase Chronic Low Back Pain Drug: AB001 patch Other: Placebo patch Phase 2 Detailed Description: This is a randomized, double-blind, placebo-controlled, parallel-group study of the safety

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>